更新于：2024-05-08
Loxoprofen Sodium Hydrate
洛索洛芬钠
更新于：2024-05-08
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C15H20NaO4 |
InChIKeyNGHFIMBWFYJBHQ-UHFFFAOYSA-N |
CAS号226721-96-6 |
关联
88
项与 洛索洛芬钠 相关的临床试验洛索洛芬钠凝胶膏随机、开放、交叉设计在中国健康受试者中的生物等效性正式试验
洛索洛芬钠凝胶贴膏人体生物等效性研究
洛索洛芬钠贴剂随机、开放、交叉设计在中国健康受试者中的生物等效性正式试验
100 项与 洛索洛芬钠 相关的临床结果
登录后查看更多信息
100 项与 洛索洛芬钠 相关的转化医学
登录后查看更多信息
100 项与 洛索洛芬钠 相关的专利（医药）
登录后查看更多信息
600
项与 洛索洛芬钠 相关的文献（医药）2024-02-15Internal Medicine
An Unusual Case of Sarcoidosis with a Prolonged Fever and Progressive Arthropathy
Article
作者: Shiota, Seiji ; Kashima, Jin ; Takasaki, Tomomi ; Ishii, Toshihiro ; Miyazaki, Eishi ; Yamamoto, Kyoko ; Doi, Eri
A 70-year-old man had developed a high fever and arthralgia in his right elbow 6 months prior. Loxoprofen improved the symptoms temporarily, but arthropathy developed in other joints. Long-term recurrent arthropathy and the fever caused activity reduction and progressive debilitation. We performed fluorine-18 fluorodeoxyglucose-positron emission tomography and detected a positive accumulation in multiple joints and lymph nodes. A lymph node biopsy revealed epithelioid cell granulomas, which, along with elevated angiotensin-converting enzyme levels, led to the diagnosis of sarcoid arthropathy. After prednisolone administration, the fever and arthralgia resolved, and his activities of daily living improved. Clinicians should be aware of this type of sarcoid arthropathy.
International Journal of Behavioral Nutrition and Physical Activity
Accelerometer-measured physical activity, sedentary behavior, and risk of incident pelvic organ prolapse: a prospective cohort study in the UK Biobank
Article
作者: Yao, Yuting ; Si, Keyi ; Qiao, Yingying ; Xu, Chenjie ; Yang, Yingying ; Dai, Qingqiang ; Liu, Qianqian ; Cao, Zhi ; Wu, Guizhu
Abstract:
Background:
Previous studies on physical activity (PA) and pelvic organ prolapse (POP) were largely limited to self-reported PA in athletes, soldiers, and women in postpartum. We aimed to investigate the association of accelerometer-measured PA and sedentary behavior with the risk of POP in middle-aged and elderly women.
Methods:
In this prospective cohort derived from the UK Biobank, the intensity and duration of PA and sedentary behavior were measured with wrist-worn accelerometers over a 7-day period in 2013–2015 for 47,674 participants (aged 42.8–77.9 years) without pre-existing POP. Participants were followed up until the end of 2022, during which incident POP was ascertained mainly by the electronic health records. Multivariable-adjusted Cox proportional hazards models and restricted cubic splines were used to assess the associations of interest. Isotemporal substitution models were applied to test the effects of substituting a type of activity with equivalent duration of others.
Results:
During a median follow-up of 8.0 years, 779 cases of POP were recorded. The duration of light-intensity PA (LPA) was positively whereas sedentary time was negatively associated with the risk of POP. Every additional 1 h/day of LPA elevated the risk of POP by 18% (95% confidence interval [CI], 10%–26%). In contrast, the risk decreased by 5% (95% CI, 0–8%) per 1 h/day increment in sedentary behavior. No associations were found between moderate-intensity PA (MPA) or vigorous-intensity PA (VPA) and POP, except that women who had a history of hysterectomy were more likely to develop POP when performing more VPA (53% higher risk for every additional 15 min/day). Substituting 1 h/day of LPA with equivalent sedentary time was associated with a 18% (95% CI, 11%–24%) lower risk of POP. The risk can also be reduced by 17% (95% CI, 7%–25%) through substituting 30 min/day of LPA with MPA.
Conclusions:
More time spent in LPA or less sedentary time was linked to an elevated risk of POP in middle-aged and elderly women, while MPA or VPA was not. Substituting LPA with equivalent duration of sedentary behavior or MPA may lower the risk of POP.
BMC Pharmacology and Toxicology
Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use
Article
作者: Onda, Kenji ; Honma, Takeshi ; Masuyama, Koichi
Abstract:
Background:
Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment and is highly effective with low-dose intermittent administration. MTX is occasionally used in combination with non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (APAP)/paracetamol for pain or inflammation control. With MTX treatment, the side effects, such as hepatotoxicity, renal failure, and myelosuppression should be considered. These are also seen with analgesics treatment.
Methods:
We used a large spontaneously reported adverse event database (FAERS [JAPIC AERS]) to analyze whether the reporting of adverse events increased upon MTX and analgesic therapy in patients with RA.
Results:
After identifying RA cases, the crude reporting odds ratios (cRORs) for hepatotoxicity, renal failure, and thrombocytopenia associated with the use of MTX, APAP, or NSAIDs were calculated by disproportionality analysis, which revealed significantly higher cRORs for these events. No analgesics showed consistent positive signals for drug-drug interaction (DDI) with concomitant low-dose MTX analyzed using four algorithms for DDI interaction (the Ω shrinkage measure, additive or multiplicative, and combination risk ratio models). However, in renal failure and thrombocytopenia, loxoprofen (Ω025 = 0.08) and piroxicam (Ω025 = 0.46), and ibuprofen (Ω025 = 0.74) and ketorolac (Ω025 = 3.52), respectively, showed positive signals in the Ω shrinkage measure model, and no consistency was found among adverse events or NSAIDs.
Conclusions:
Studies using spontaneous reporting systems have limitations such as reporting bias or lack of patient background; however, the results of our comprehensive analysis support the results of previous clinical or epidemiological studies. This study also demonstrated the usefulness of FAERS for DDI assessment.
100 项与 洛索洛芬钠 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 疼痛 | 批准上市 | 墨西哥 更多 | |
| 炎症 | 批准上市 | 中国 更多 | |
| 术后疼痛 | 批准上市 | 韩国 更多 | |
| 白内障 | 临床2期 | 中国 更多 | |
| 眼部炎症 | 无进展 | 中国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 451 | (People living with HIV) | 夢網蓋窪獵襯衊壓網蓋(廠鑰壓夢鏇淵艱願積範) = 衊襯夢糧糧獵廠鬱鬱選 窪鹹夢襯觸襯願憲襯艱 (鏇簾鑰獵齋憲積範醖顧, 5.1 ~ 36) | - | 2022-01-01 | ||
临床2期 | 47 | (Experimental) | 獵選遞鏇鹹願憲糧築鬱(顧糧網鹽構鬱衊網鬱艱) = 觸選艱觸窪獵繭衊築廠 築觸廠蓋壓顧獵齋糧廠 (築製願遞積艱鹹鬱膚顧, 鬱淵鬱鑰憲憲膚襯蓋構 ~ 膚膚淵艱積鹹願膚觸製) 更多 | - | 2019-09-09 | ||
(Placebo Comparator) | 獵選遞鏇鹹願憲糧築鬱(顧糧網鹽構鬱衊網鬱艱) = 獵獵觸壓構餘簾積憲繭 築觸廠蓋壓顧獵齋糧廠 (築製願遞積艱鹹鬱膚顧, 衊製夢廠網憲範壓襯顧 ~ 願選醖鑰夢繭遞夢淵鏇) 更多 | ||||||
临床3期 | 80 | 衊壓繭齋構願艱齋壓願(壓鑰觸廠鹽簾窪衊簾簾) = 憲獵醖醖築遞蓋淵選鹽 簾願餘艱鹹淵網積築壓 (繭醖齋獵網簾壓齋鹹網, 築齋壓鬱顧選壓積壓簾 ~ 夢遞網願醖鹽齋鏇鑰遞) 更多 | - | 2018-07-20 | |||
临床4期 | 一线 | 190 | 壓築簾艱夢壓鏇鬱衊網(簾餘醖鬱醖蓋觸齋蓋衊) = 繭衊積顧遞顧網艱遞壓 積襯糧簾蓋廠窪製製顧 (鏇鑰醖鏇獵築窪衊觸餘 ) | 积极 | 2013-02-01 | ||
壓築簾艱夢壓鏇鬱衊網(簾餘醖鬱醖蓋觸齋蓋衊) = 壓遞廠顧淵積鬱憲窪壓 積襯糧簾蓋廠窪製製顧 (鏇鑰醖鏇獵築窪衊觸餘 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用